Zidesamtinib efficacy and safety in patients with advanced ROS1-positive solid tumors other than non-small cell lung cancer in the ARROS-1 study
NCODA Oncology and Hematology Meeting Abstracts · 13.10.2026 · 2 (2)
DOI: 10.67209/ldrl4393 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 13.10.2026. Verfasst von Benjamin Solomon und 17 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Gefördert von: Nuvalent, Inc..
Abstract (Originalsprache)
Background
ROS1 fusions are oncogenic drivers in various cancers. Multiple ROS1 tyrosine kinase inhibitors (TKIs) are available for ROS1-positive non-small cell lung cancer (NSCLC); however, there are limited data on the activity of these agents in patients with other ROS1-positive tumors. In patients with advanced ROS1-positive NSCLC (TKI-pretreated and TKInaïve), zidesamtinib has demonstrated encouraging clinical activity, including in patients with central nervous system (CNS) disease and/or ROS1 G2032R mutation, and a safety profile consistent with its highly ROS1-selective design.
Objectives
Evaluate the efficacy of zidesamtinib in patients with advanced or metastatic ROS1-positive solid tumors other than NSCLC in the ARROS-1 study. Describe safety outcomes in patients with ROS1-positive solid tumors other than NSCLC treated with zidesamtinib in ARROS-1.
Purpose
To evaluate the antitumor activity and safety of zidesamtinib in patients with advanced ROS1-positive solid tumors other than NSCLC. Study Design: The global phase 1/2 ARROS-1 study (NCT05118789) includes a cohort of patients with advanced or metastatic ROS1-positive solid tumors other than NSCLC whose disease has progressed on any prior therapy.
Methods
Key endpoints are objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review (BICR), duration of response (DOR), and safety. The data cutoff date was September 22, 2025.
Results
Overall, 15 efficacy-evaluable patients with ROS1-positive solid tumors (10 non-NSCLC tumor types) received zidesamtinib. Patients received a median of 2 prior anticancer therapies (range, 1–6); 60% were ROS1 TKI-naïve, 40% were ROS1 TKI-pretreated (range, 1–2), and 73% had received prior lines of chemotherapy (range, 1–4). The ORR was 40% (6/15, including 1 partial response pending confirmation), with no disease progression by BICR among responders (DOR range, 3.9+ to 22.8+ months). Responses were observed across multiple tumor types, including cholangiocarcinoma, colorectal cancer, gastric cancer, inflammatory myofibroblastic tumor, ovarian cancer, and pancreatic cancer. Two ROS1 TKI-pretreated patients had ROS1 resistance mutations (G2032R and F2004I/F2004V) at baseline, and both achieved a partial response (1 pending confirmation). Treatment-related adverse events (TRAEs) in ≥15% of patients were increased alanine aminotransferase, increased blood creatine phosphokinase, and dysgeusia (3 patients each). No patient discontinued zidesamtinib due to TRAEs, and 1 patient had a dose reduction due to a TRAE.
Conclusion
Zidesamtinib demonstrated encouraging activity in patients with diverse ROS1-positive solid tumors, including those refractory to standard-of-care therapies. The safety profile of zidesamtinib was consistent with its ROS1-selective design. Enrollment is ongoing. Funding: Nuvalent, Inc. Prior Presentations: Presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026, in Chicago, IL, USA. © 2026 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2026 ASCO Annual Meeting. All rights reserved.
Förderung
- Nuvalent, Inc.
Zitieren
APA
Solomon, B., Popat, S., Felip, E., Drilon, A., Besse, B., Ninomiya, K., Hayashi, H., Yoshida, T., Owen, D., Yarza, R., Ariyasu, R., Akamatsu, H., Garassino, M., Baik, C., Samant, M., Zhang, B., Upadhyay, V., & Wolf, J. (2026). Zidesamtinib efficacy and safety in patients with advanced ROS1-positive solid tumors other than non-small cell lung cancer in the ARROS-1 study. NCODA Oncology and Hematology Meeting Abstracts, 2(2). https://doi.org/10.67209/ldrl4393
Vancouver
Solomon B, Popat S, Felip E, Drilon A, Besse B, Ninomiya K, et al. Zidesamtinib efficacy and safety in patients with advanced ROS1-positive solid tumors other than non-small cell lung cancer in the ARROS-1 study. NCODA Oncology and Hematology Meeting Abstracts. 2026;2(2). doi:10.67209/ldrl4393
BibTeX
@article{Solomon2026,
author = {Solomon, Benjamin and Popat, Sanjay and Felip, Enriqueta and Drilon, Alexander and Besse, Benjamin and Ninomiya, Kiichiro and Hayashi, Hidetoshi and Yoshida, Tatsuya and Owen, Dwight and Yarza, Ramon and Ariyasu, Ryo and Akamatsu, Hiroaki and Garassino, Marina and Baik, Christina and Samant, Manoj and Zhang, Bo and Upadhyay, Vivek and Wolf, Jürgen},
title = {Zidesamtinib efficacy and safety in patients with advanced ROS1-positive solid tumors other than non-small cell lung cancer in the ARROS-1 study},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
volume = {2},
number = {2},
doi = {10.67209/ldrl4393}
}
EUVIMED